Free Trial

Replimune Group (REPL) Stock Price, News & Analysis

Replimune Group logo
$5.67 +0.07 (+1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$5.74 +0.07 (+1.15%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Replimune Group Stock (NASDAQ:REPL)

Key Stats

Today's Range
$5.53
$5.82
50-Day Range
$2.81
$12.63
52-Week Range
$2.68
$17.00
Volume
2.27 million shs
Average Volume
17.49 million shs
Market Capitalization
$442.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67
Consensus Rating
Hold

Company Overview

Replimune Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

REPL MarketRank™: 

Replimune Group scored higher than 89% of companies evaluated by MarketBeat, and ranked 130th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Replimune Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Replimune Group has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Replimune Group's stock forecast and price target.
  • Earnings Growth

    Earnings for Replimune Group are expected to grow in the coming year, from ($2.97) to ($2.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Replimune Group is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Replimune Group is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Replimune Group has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    28.80% of the float of Replimune Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Replimune Group has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Replimune Group has recently increased by 165.71%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Replimune Group does not currently pay a dividend.

  • Dividend Growth

    Replimune Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    28.80% of the float of Replimune Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Replimune Group has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Replimune Group has recently increased by 165.71%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Replimune Group has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 30 news articles for Replimune Group this week, compared to 7 articles on an average week.
  • Search Interest

    Only 26 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
  • MarketBeat Follows

    Only 17 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,157.00 in company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Replimune Group is held by insiders.

  • Percentage Held by Institutions

    92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Replimune Group's insider trading history.
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Headlines

REPL Stock Analysis - Frequently Asked Questions

Replimune Group's stock was trading at $12.11 on January 1st, 2025. Since then, REPL stock has decreased by 53.2% and is now trading at $5.67.

Replimune Group, Inc. (NASDAQ:REPL) posted its earnings results on Thursday, August, 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.12.

Replimune Group (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Top institutional investors of Replimune Group include Redmile Group LLC (5.98%), Marshall Wace LLP (2.39%), Geode Capital Management LLC (2.09%) and Sofinnova Investments Inc.. Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Sushil Patel, Pamela Esposito, Konstantinos Xynos, Tanya Lewis, Emily Luisa Hill, Christopher Sarchi and Andrew Schwendenman.
View institutional ownership trends
.

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD).

Company Calendar

Last Earnings
8/07/2025
Today
8/22/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:REPL
CIK
1737953
Fax
N/A
Employees
210
Year Founded
2015

Price Target and Rating

High Price Target
$22.00
Low Price Target
$2.00
Potential Upside/Downside
+33.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$247.30 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.34%
Return on Assets
-52.81%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
6.94
Quick Ratio
6.94

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.31 per share
Price / Book
1.33

Miscellaneous

Outstanding Shares
78,056,000
Free Float
73,997,000
Market Cap
$446.87 million
Optionable
Optionable
Beta
0.67
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:REPL) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners